Study of ocrelizumab injections for children with relapsing-remitting MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if ocrelizumab, given as a shot under the skin, is safe and works for children and teens with relapsing-remitting multiple sclerosis (RRMS). It aims to help control relapses and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 10 and 18 years old (not yet 18).
- You weigh at least 55 pounds (25 kilograms).
- You have a diagnosis of relapsing-remitting multiple sclerosis (RRMS).
- Your MS symptoms have been steady for at least 30 days before the study starts.
- You have a disability score (EDSS) between 0 and 5.5 at screening (mild to moderate disability).
- You have had all the standard childhood vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
This trial tests a new study drug added to your current MS treatment (ocrelizumab) for people with progressive MS. It aims to see if the combination works better than ocrelizumab alone.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Hear when a new Relapsing-remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.